Use of IGFBP-7 in the assessment of heart failure

US10996229B2 · kind B2 · utility

Assignees

• Roche Diagnostics Operations, Inc. · US
• The Governing Council of the University of Toronto · CA

Inventors

• Ursula-Henrike Wienhues-Thelen · Krailling, DE
• Georg Hess · Mainz, DE
• Hendrik Huedig · Penzberg, DE
• Herbert von der Eltz · Weilheim, DE
• Andrew Emili · Needham, US
• Anthony Gramolini · Toronto, CA
• Peter Liu · Toronto, CA
• David MacLennan · Toronto, CA
• Vincent Fong · Markham, CA
• Ruth Isserlin · Thornhill, CA
• Thomas Kislinger · Toronto, CA
• Dirk Block · Bichl, DE

Key dates

• Filing date: Oct 10, 2019
• Grant date: May 4, 2021
• Expiry date: Oct 10, 2039

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/56
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.